The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Comparison of Pharmacokinetics and Dynamics of the Long-Acting Insulin Analogs Glargine and Detemir at Steady State in Type 1 Diabetes
Open accessAbstract
OBJECTIVE—To compare pharmacokinetics and pharmacodynamics of insulin analogs glargine and detemir, 24 subjects with type 1 diabetes (aged 38 ± 10 years, BMI 22.4 ± 1.6 kg/m2, and A1C 7.2 ± 0.7%) were studied after a 2-week treatment with either glargine or detemir once daily (randomized, double-blind, crossover study). RESEARCH DESIGN AND METHODS—Plasma glucose was clamped at 100 mg/dl for 24 h after subcutaneous injection of 0.35 unit/kg. The primary end point was end of action (time at which plasma glucose was >150 mg/dl). RESULTS—With glargine, plasma glucose remained at 103 ± 3.6 mg/dl up to 24 h, and all subjects completed the study. Plasma glucose increased progressively after 16 h with detemir, and only eight subjects (33%) completed the study with plasma glucose <180 mg/dl. Glucose infusion rate (GIR) was similar with detemir and glargine for 12 h, after which it decreased more rapidly with detemir (P < 0.001). Estimated total insulin activity (GIR area under the curve [AUC]0–end of GIR) was 1,412 ± 662 and 915 ± 225 mg/kg (glargine vs. detemir, P < 0.05), with median time of end of action at 24 and 17.5 h (glargine vs. detemir, P < 0.001). The antilipolytic action of detemir was lower than that of glargine (AUC free fatty acids0–24 h 11 ± 1.7 vs. 8 ± 2.8 mmol/l, respectively, P < 0.001). CONCLUSIONS—Detemir has effects similar to those of glargine during the initial 12 h after administration, but effects are lower during 12–24 h.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Standards of Medical Care in Diabetes—2007
American Diabetes Association (2007) · Diabetes Care · doi:10.2337/dc07-s004 · Cited by 1,190
Lepore, M., Pampanelli, S., Fanelli, C., Porcellati, F., Bartocci, L., Di Vincenzo, A., Cordoni, C., Costa, E., Brunetti, P., & Bolli, G. B. (2000) · Diabetes · doi:10.2337/diabetes.49.12.2142 · Cited by 818
Self-citationKurtzhals, P., Schäffer, L., Sørensen, A., Kristensen, C., Jonassen, I., Schmid, C., & Trüb, T. (2000) · Diabetes · doi:10.2337/diabetes.49.6.999 · Cited by 739 · cited 1×
“This reflects the in vitro data where detemir is estimated to possess only ~27% lipogenic potency vs human insulin ( 24 ).”
BackgroundCross‐over Trials In Clinical Research
Senn, S. (2002) · doi:10.1002/0470854596 · Cited by 653
Heise, T., Nosek, L., Rønn, B. B., Endahl, L., Heinemann, L., Kapitza, C., & Draeger, E. (2004) · Diabetes · doi:10.2337/diabetes.53.6.1614 · Cited by 614
Vague, P., Selam, J.-L., Skeie, S., De Leeuw, I., Elte, J. W. F., Haahr, H., Kristensen, A., & Draeger, E. (2003) · Diabetes Care · doi:10.2337/diacare.26.3.590 · Cited by 294 · cited 1×
“These PK and PD advantages translate into a reduced risk of nocturnal hypoglycemia in T1DM vs NPH ( 6-9 ).”
BackgroundKlein, O., Lynge, J., Endahl, L., Damholt, B., Nosek, L., & Heise, T. (2007) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2006.00685.x · Cited by 251 · cited 2×
“These considerations are likely to account for the different findings of PK and PD in the present study as compared to previous studies in T2DM (28), especially with parallel groups ( 27 ).”
BackgroundResult
Cited by
Rosenstock, J., Davies, M., Home, P. D., Larsen, J., Koenen, C., & Schernthaner, G. (2008) · Diabetologia · doi:10.1007/s00125-007-0911-x · Cited by 447
Diabetes: Advances in Diagnosis and Treatment
Nathan, D. M. (2015) · JAMA · doi:10.1001/jama.2015.9536 · Cited by 384
Bretzel, R. G., Nuber, U., Landgraf, W., Owens, D. R., Bradley, C., & Linn, T. (2008) · The Lancet · doi:10.1016/s0140-6736(08)60485-7 · Cited by 305
Self-citationThe evolution of insulin and how it informs therapy and treatment choices
Hirsch, I. B., Juneja, R., Beals, J. M., Antalis, C. J., & Wright, E. E. (2020) · Endocrine Reviews · doi:10.1210/endrev/bnaa015 · Cited by 237
Insulin therapy for type 2 diabetes.
Swinnen, S. G., Hoekstra, J. B., & DeVries, J. H. (2009) · Diabetes Care · doi:10.2337/dc09-s318 · Cited by 181
Metadata
- Authors
- Porcellati, F., Rossetti, P., Busciantella, N. R., Marzotti, S., Lucidi, P., Luzio, S., Owens, D. R., Bolli, G. B., & Fanelli, C. G.
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2007-10-01
- Volume
- 30
- Issue
- 10
- Pages
- 2447-2452
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- OpenAlex
- W2133807304
- Cited by
- 219
- References
- 7
- FWCI
- 13.53
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Comparison of Pharmacokinetics and Dynamics of the Long-Acting Insulin Analogs Glargine and Detemir at Steady State in Type 1 Diabetes. https://app.cochat.ai/papers/10.2337/dc07-0002
- The paper
- Porcellati, F., Rossetti, P., Busciantella, N. R., Marzotti, S., Lucidi, P., Luzio, S., Owens, D. R., Bolli, G. B., & Fanelli, C. G. (2007). Comparison of Pharmacokinetics and Dynamics of the Long-Acting Insulin Analogs Glargine and Detemir at Steady State in Type 1 Diabetes. Diabetes Care. https://doi.org/10.2337/dc07-0002
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.